Imatinib and beyond—the new CML study IV: A randomized controlled comparison of imatinib vs imatinib/interferon-alpha vs imatinib/low-dose AraC vs imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia

By Berger U.  

Annals of Hematology, Vol. 83, Iss. 4, 2004-04 ,pp. : 258-264

Springer Publishing Company

Access to resources Recommend Favorite

High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia. A prospective randomized phase III study

By Deenik W.   Holt B.   Verhoef G.   Schattenberg A.   Verdonck L.   Daenen S.   Zachée P.   Westveer P.   Smit W.   Wittebol S.   Schouten H.   Löwenberg B.   Ossenkoppele G.   Cornelissen J.  

Annals of Hematology, Vol. 86, Iss. 2, 2007-02 ,pp. : 117-125

Springer Publishing Company

Access to resources Recommend Favorite

Effect of LMO2 protein expression on survival in chronic myeloid leukemia patients treated with imatinib mesylate

By Sonmez Mehmet   Akagun Tulin   Cobanoglu Umit   Topbas Murat   Erkut Nergiz   Yilmaz Mustafa   Ovali Ercument   Omay Serdar Bedii  

Hematology, Vol. 14, Iss. 4, 2009-08 ,pp. : 220-223

Maney Publishing

Access to resources Recommend Favorite

The proto-oncogene expression varies over the course of chronic myeloid leukemia

By Vidović Ana   Janković Gradimir   Čolović Milica   Tomin Dragica   Peruničić Maja   Bila Jelena   Marković Olivera   Bošković Darinka  

Hematology, Vol. 13, Iss. 1, 2008-02 ,pp. : 34-40

Maney Publishing

Access to resources Recommend Favorite

Imatinib Mesylate in Chronic Myeloid Leukemia

By  

Current Stem Cell Research & Therapy, Vol. 2, Iss. 3, 2007-09 ,pp. : 249-251

Bentham Science Publishers

Access to resources Recommend Favorite